| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94b51d317764e2f4f1bbcb355b274c8b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4162
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4162
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-56 |
| filingDate |
2010-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f81a7262874756b09a4097e5081265a6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8459de5abf79da5fa2cec0613f6850f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e736e2885f8cbca1e1973725a516c588
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe9f0989ed6b957d822dfcc2b67d62f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8bf1a0b7f792bdad0f3d6d1a8a297ca6 |
| publicationDate |
2012-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20120069658-A |
| titleOfInvention |
Ronidamine analogues for fertility control |
| abstract |
Fertility control may include administering to the subject one or more doses of the compound according to Formula (I) to reduce fertility in the subject. Fertility control also impairs Sertoli cell function in male targets; Inhibit spermatogenesis in the subject; Reduce testicular weight at the target; Reducing ovarian weight in female subjects; Reducing serum progesterone in female subjects; Impaired ovarian follicle function in female subjects; Administering an effective amount of the compound to cause reversible infertility in the subject. In order to regain fertility, the method may comprise discontinuing administration of the compound to the subject to regain fertility in the subject. The compound can be administered to irreversibly infertile the subject. |
| priorityDate |
2009-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |